Effective immediately, Oxidative Burst by Flow Cytometry (#LAB2111414) will no longer require submission of the biological mother’s sample. An adult control specimen will still be required along with the patient’s specimen. For more information on specimen collection, please visit the Laboratory Catalog.
Questions may be directed to the Flow Cytometry Laboratory using the “Contact Us” link above.
Effective immediately, the anion gap reference interval will be changed from 4-15 mmol/L to 9-18 mmol/L to reflect the system-wide standardization of electrolyte testing.
Effective immediately, Michigan Blood no longer provides 5-pack platelets and Spectrum Health Blood Bank has changed nomenclature for platelet units when they are ordered. In the past, platelets were ordered as a 5-pack which came from 5 separate donors and had a volume of 250 mL. Current process is one single unit of pheresed platelets which comes from a single donor. The volume is 250 mL, an equivalent volume as a 5-pack of pooled random donor platelets. The bonus is that there are now fewer donor exposures when transfusing a unit of platelets. The 5:5:1 ratio still applies for MTPs (massive transfusions).
Questions may be directed to the Blood Bank using the “Contact Us” link above.
An updated BCR-ABL1 t[9;22] RT-PCR assay went live on Jan 31, 2018. The BCR-ABL major and minor fusion transcripts are measured and reported separately after this update. The quantities of BCR-ABL1 major breakpoints fusion transcripts (type e13a2 and/or e14a2) are detected by FDA approved QuantideX® qPCR BCR-ABL IS Kit and the result is calibrated and reported on the International Scale (%IS). The quantities of BCR-ABL minor fusion transcripts are detected by QuantideX qPCR BCR-ABL minor kit and the result is reported as BCR-ABL1 to ABL1 ratio (%). This update provides more precise and standard measurements of BCR-ABL fusion RNA and supports the consistency of patient care in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).
Questions may be directed to the Molecular Diagnostics Laboratory using the “Contact Us” link above.
Lab Catalog link: LAB3222022: BCR-ABL1 t[9;22] RT- PCR
As of May 8, 2018, the following tests are no longer performed by Spectrum Health Laboratory. These tests are now available through Mayo Medical Laboratories as a send out. Please note that the specimen collection for these tests may have changed. Please check the Laboratory Catalog for collection information.
|Discontinued Test Code||Discontinue Test Name||Replacement Code||Replacement Name|
|LAB752||Clomipramine Level||LAB1230481||Clomipramine, Serum|
|LAB683||Ethosuximide Level||LAB1230480||Ethosuximide, Serum|
Questions may be directed to the Toxicology Department using the “Contact Us” link above.
High sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria (PNH) is a test done on patient’s peripheral blood to screen for the presence or absence of PNH clones and/or to follow PNH clonal populations. The lower limit of detection of a PNH clone for the Spectrum Health laboratory has been validated as 0.01% (1:10,000) for red cells, 0.01% (1:10,000) for granulocytes and 0.1% for monocytes (1:1000).
The results from PNH flow cytometry testing can guide the clinical team in classifying a patient’s disease appropriately, analyzing the risk of disease progression, and choosing appropriate testing to monitor response to treatment. Therefore, the PNH flow cytometry test result will now include a pathologist’s interpretation based on the new recommendations given in Updated ICCS/ESCCA Consensus Guidelines for the Clinical Utility of Testing for GPI-Anchor Deficient Clones in Paroxysmal Nocturnal Hemoglobinuria (PNH) and other Bone Marrow Disorders (Accepted article by Dezern and Borowitz, doi: 10.1002/cyto.b.21608).